David N Gill insider trades
Open-market stock purchases and sales by David N Gill, Director at Evolus, Inc, from SEC Form 4 filings since Apr 2, 2012.
Track record: 0% of 2 scored buys are up 5% or more since purchase, averaging -30%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Feb 17, 2026 | EOLS Evolus, Inc | Bought (not open market) | — |
Companies traded
- EOLS Evolus, Inc: 2 buys, 4 sales, last Feb 17, 2026
- YMAB Y-mAbs Therapeutics, Inc: 3 sales, last Sep 16, 2025
- SBBP Strongbridge Biopharma plc: 1 buy, last Oct 5, 2021
- SSKN STRATA Skin Sciences, Inc: other filings, last Nov 22, 2019
- MLNT Melinta Therapeutics, Inc /new/: 1 buy, last Jun 11, 2019
- HSGX Histogenics Corp: 4 buys, last Jun 15, 2018
- CEMP Cempra, Inc: 1 buy, last Jan 3, 2017
- GI EndoChoice Holdings, Inc: 2 buys, last Nov 22, 2016